netFormulary Leicestershire Health Community NHS
Medicines Formulary  
 Search
 Formulary Chapter 5: Infections - Full Chapter
Chapter Links...
 Details...
05.03.03  Expand sub section  Viral hepatitis
Daclatasvir
View adult BNF View SPC online  Track Changes
Restricted Drug Restricted
Red
High Cost Medicine
NHS England
BlueTeq

Specialist prescribing in Hepatitis C
Commissioned by NHSE in line with NICE TA only
Blueteq prior approval required before initiation



Date of entry of decision to formulary: February 2016

 
Link  NICE TA 364: Daclatasvir for treating chronic hepatitis C
   
Dasabuvir
View adult BNF View SPC online  Track Changes
Restricted Drug Restricted
Red
High Cost Medicine
NHS England
BlueTeq

Specialist use in Hepatitis C
NHSE commissioned in line with NICE TA 365
Blueteq prior approval required before intiation
Date of entry of decision to Formulary: March 2016

 
Link  NICE TA 365: Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C
   
Elbasvir and grazoprevir (Zepatier®)
View adult BNF View SPC online  Track Changes
Restricted Drug Restricted
Red
High Cost Medicine
NHS England
BlueTeq

Specialist use in Hepatitis C
NHSE commissioned in line with NICE TA 413
Blueteq prior approval required before initiation
Date of entry of decision to formulary: January 2017

 
Link  NICE TA 413: Elbasvir–grazoprevir for treating chronic hepatitis C
   
Entecavir
View adult BNF View SPC online  Track Changes
Restricted Drug Restricted
Red
High Cost Medicine
Specialist prescribing in Hepatitis B
Commissioned by NHSE in line with NICE TA 153 only 
Link  NICE TA 153: Entecavir for the treatment of chronic hepatitis B
   
Glecaprevir and pibrentasvir (Maviret®)
View adult BNF View SPC online  Track Changes
Restricted Drug Restricted
Red
High Cost Medicine
BlueTeq

Specialist prescribing for hepatitis C.
NHSE Commissioned in line with NICE TA 499 only. 
Blueteq prior approval required before initiation

Date of entry of decision to Formulary: February 2018

 
Link  NICE TA 499: Glecaprevir–pibrentasvir for treating chronic hepatitis C
   
Ledipasvir and sofosbuvir  (Harvoni®)
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Red
High Cost Medicine
NHS England
BlueTeq

Specialist prescribing in Hepatitis C
Commissioned by NHSE in line with NICE TA only
Blueteq prior approval required before initiation

Date of entry of decision to formulary: February 2016

 
Link  NICE TA 363: Ledipasvir–sofosbuvir for treating chronic hepatitis C
   
Ombitasvir, paritaprevir, and ritonavir  (Viekirax®)
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Red
High Cost Medicine
NHS England
BlueTeq

Specialist prescribing in Hepatitis C
NHSE commissioned in line with NICE TA only with or without Dasabuvir
Blueteq prior approval required before initiation


Date of entry of decision to formulary: February 2016

 
Link  NICE TA 365: Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C
   
Simeprevir
View adult BNF View SPC online  Track Changes
Restricted Drug Restricted
Red
High Cost Medicine
NHS England

Specialist prescribing in Hepatitis C
Commissioned by NHSE in line with NICE TA only.

Genotype 4 patients require Blueteq prior approval before initiation

Date decision added to Formulary: May 15

 
Link  NICE TA 331: Simeprevir for chronic Hepatitis C
   
Sofosbuvir
View adult BNF View SPC online  Track Changes
Restricted Drug Restricted
Red
High Cost Medicine
NHS England
BlueTeq

Specialist prescribing in Hepatitis C
NHSE commissioned in line with NICE TA only
Blueteq prior approval required before initiation

Date decision added to Formulary: May 15

 
Link  NICE TA 330: Sofosbuvir for chronic Hepatitis C
   
Sofosbuvir, velpatasvir, voxilaprevir (Vosevi®)
View adult BNF View SPC online  Track Changes
Restricted Drug Restricted
Red
High Cost Medicine
NHS England
BlueTeq

Specialist prescribing in Hepatitis C

NHSE commissioned in line with NICE TA 507 only 
Blueteq prior approval required before initiation 

Date of entry of decision to formulary: May 2018

 
Link  NICE TA 507: Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C
   
Sofosbuvir/valpatasvir (Epclusa®)
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Red
High Cost Medicine
NHS England
BlueTeq

Specialist prescribing in Hepatitis C
NHSE commissioned in line with NICE TA only
Blueteq prior approval required before initiation

Date decision added to Formulary: March 17

 
Link  NICE TA 430: Sofosbuvir–velpatasvir for treating chronic hepatitis C
   
Boceprevir
View adult BNF View SPC online  Track Changes
Restricted Drug Restricted
Red
High Cost Medicine
BlueTeq

Specialist prescribing in Hepatitis C
Commissioned by NHSE in line with NICE TA 253 only

Date of entry of decision to Formulary: May 2012

Use superceded by newer drugs for Hepatitis C

Blueteq prior approval required before initiation

 
Link  NICE TA 253: Boceprevir for the treatment of genotype 1 chronic hepatitis C
   
Telaprevir
View adult BNF View SPC online  Track Changes
Restricted Drug Restricted
Red
NHS England
BlueTeq

Specialist prescribing in Hepatitis C
High cost drug excluded to tariff. Commissioned by NHSE in line with NICE TA 252 only

Date of entry of decision to Formulary: May 2012

Use superceded by newer drugs for Hepatitis C

 
Link  NICE TA 252:Telaprevir for the treatment of genotype 1 chronic hepatitis C
   
 ....
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Black

Drugs not recommended for use in the Leicestershire Health Community because of lack of evidence of clinical effectiveness, cost prioritization or concerns over safety. All new drugs will be black until they have been through the appropriate approval process - then they will appear as a specific entry   

Red

Drugs which should be prescribed only by hospital specialists (clinical review by specialist as appropriate and annually as a minimum).  

Amber SCA

Drugs which would initially be prescribed by a hospital specialist and then by a GP where full agreement to share the care of each specific patient has been reached under a LMSG Shared Care Agreement (SCA). Specific patient monitoring or intervention required.   

Amber Simple

Drugs suitable to be initiated and prescribed in primary care only after specialist assessment and recommendation. A shared care agreement is not required.  

Green Conditional

Drugs for which GPs are able to take full responsibility for prescribing and monitoring subject to specified conditions e.g. prescribing in line with agreed LMSG guidance or able to demonstrate suitable competence see comments under individual entries.   

Green

Drugs for which GPs would normally take full responsibility for prescribing and monitoring. Drugs included in this list have been specifically considered by LMSG.   

netFormulary